The relationship of preptin level with cardiovascular risk factors in metabolic syndrome

Metabolic syndrome is an endocrinopathy in which systemic disorders such as abdominal obesity, glucose intolerance or diabetes mellitus, hypertension, coronary artery disease (CAD) and dyslipidemia first appear with insulin resistance. In the metabolic syndrome, which is a serious problem in the world, it has been suggested that the frequency of occurrence and the individual characteristics and lifestyles of the subjects and the time interval during which the research was conducted. It has been suggested that the presence of subclinical cardiovascular diseases in people with metabolic syndrome is also effective in increasing the risk of cardiovascular disease. The rapidly spreading diabetes and metabolic syndrome in the world has directed researchers to investigate the molecules involved in the diagnosis, treatment and pathogenesis of these diseases. As a result of these studies, it is hopeful that cardiovascular diseases can be prevented. Our aim in our study is to examine the relationship of preptin, a recently discovered peptide, with metabolic syndrome and to evaluate its relation with cardiovascular risk factors. 58 metabolic syndrome patients were included in the study as experimental group and 30 healthy individuals as control group. Risk assessment of preptin, age, waist circumference, hip circumference, systolic blood pressure, diastolic blood pressure, glucose, insulin, LDL, HDL, total cholesterol, triglyceride, HOMA, HbA1c, BMI, QUICKI, SCORE was significantly higher in patients with metabolic syndrome compared to the control group. (respectively p=0,000, p=0,000, p=0,000, p=0,000, p=0,000, p=0,000, p=0,005, p=0,000, p=0,000 p=0,008, p=0,000, p=0,033, p=0,000, p=0,043, p=0,000, p=0,000,p=0,000). In the correlation analysis applied to the metabolic syndrome patient group, a positive correlation was found between Preptin level and waist circumference, systolic blood pressure, HOMA and BMI. (respectively r=0,324 p<0,005, r=0,293 p<0,05, r=0,332 p<0,05, r=0,308 p<0,05). Metabolic syndrome patient group were evaluated for relationship between BMI and SCORE with preptin levels under 4 different subgroups. As BMI and SCORE risk increased, preptin levels also increased. As BMI and SCORE risk increased, preptin levels also increased. Consecuently, it has been predicted that due to its elevated levels in patients with metabolic syndrome, preptin may be a peptide that may assist in determining cardiovascular risk factors. Key Words: Metabolic Syndrome, Preptin, Cardiovasculer risk, Insulin rezistance, Hyperlipidemia, HOMA.